Table 2.
Susceptibility or resistance category | Total cases | New cases | Previously treated cases | ||||||
---|---|---|---|---|---|---|---|---|---|
2006 (n = 255) n (%) |
2012 (n = 537) n (%) |
P value | 2006 (n = 176) n (%) |
2012 (n = 318) n (%) |
P value | 2006 (n = 79) n (%) |
2012 (n = 219) n (%) |
P value | |
Any drug-resistance | 89 (34.9) | 292 (54.4) | <0.001 | 37 (21.0) | 115 (36.2) | 0.001 | 52 (65.8) | 177 (80.8) | 0.007 |
All first-line drug resistance | 78 (30.6) | 269 (50.1) | <0.001 | 30 (17.0) | 98 (30.8) | 0.001 | 48 (60.8) | 171 (78.1) | 0.003 |
INH | 60 (23.5) | 209 (38.9) | <0.001 | 20 (11.4) | 57 (17.9) | 0.054 | 40 (50.6) | 152 (69.4) | 0.003 |
RIF | 43 (16.9) | 164 (30.5) | <0.001 | 5 (2.8) | 30 (9.4) | 0.006 | 38 (48.1) | 134 (61.2) | 0.044 |
STR | 59 (23.1) | 189 (35.2) | 0.001 | 21 (11.9) | 63 (19.8) | 0.026 | 38 (48.1) | 126 (57.5) | 0.149 |
EMB | 24 (9.4) | 88 (16.4) | 0.008 | 8 (4.5) | 31 (9.7) | 0.040 | 16 (20.3) | 57 (26.0) | 0.306 |
All MDR | 38 (14.9) | 145 (27.0) | <0.001 | 5 (2.8) | 21 (6.6) | 0.073 | 33 (41.8) | 124 (56.6) | 0.023 |
INH + RIF | 4 (2.0) | 25 (4.5) | 0.079 | 1 (0.6) | 4 (1.3) | 0.463 | 3 (3.8) | 21 (9.6) | 0.105 |
INH + RIF + STR/EMB | 34 (13.3) | 120 (22.3) | 0.003 | 4 (2.3) | 17 (5.3) | 0.105 | 30 (38.0) | 103 (47.0) | 0.165 |
All second-line drug resistance | 40 (15.7) | 172 (32.0) | <0.001 | 14 (8.0) | 45 (14.2) | 0.042 | 26 (32.9) | 127 (58.0) | <0.001 |
OFX | 37 (14.5) | 164 (30.5) | <0.001 | 13 (7.4) | 42 (13.2) | 0.049 | 24 (30.4) | 122 (55.7) | <0.001 |
CAP | 1 (0.4) | 29 (5.4) | 0.001 | 1 (0.6) | 2 (0.6) | 0.934 | 0 | 27 (12.3) | 0.001 |
AMK | 9 (3.5) | 42 (7.8) | 0.021 | 1 (0.6) | 7 (2.2) | 0.168 | 8 (10.1) | 35 (16.0) | 0.204 |
All pre-XDR | 17 (6.7) | 73 (13.6) | 0.004 | 2 (1.1) | 10 (3.1) | 0.165 | 15 (19.0) | 63 (28.8) | 0.090 |
All XDR | 6 (2.4) | 36 (6.9) | 0.008 | 1 (0.6) | 4 (1.3) | 0.463 | 5 (6.3) | 32 (14.6) | 0.056 |